A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

This study aims to provide a basis for further clinical development of YK012.

Trial Details

NCT ID
NCT06565689
Phase
PHASE1
Sponsor
Excyte Biopharma Ltd
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • YK012
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Written informed consent obtained from the patient prior to performing any study-related procedures, including screening visits.
  • Males or females aged ≥ 18 to ≤ 65 years.
  • Participants with an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 1.
  • Participants with an estimated survival time of more than 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →